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Abstract 
Objective 
The Delphi method is commonly used to achieve consensus in core outcome set (COS) development. 
It is important to try to maximise response rates to Delphi studies, minimise attrition rates and 
potential for bias. The factors that impact response rates in a Delphi study used for COS development 
are unknown. The objective of this study was to explore the impact of design characteristics on 
response rates in Delphi surveys within COS development. 
Study design 
Published and ongoing studies that included Delphi to develop a COS were eligible. Second round 
voting response rates were analysed, and multilevel linear regression was conducted to investigate 
whether design characteristics were associated with response rate. 
Results  
Thirty-one studies were included. Two characteristics were significantly associated with a lower 
response rate: larger panels and studies with more items included.  
Conclusion  
COS developers should pay attention to methods when designing a COS development study, in 
particular the size of the panels and the size of the list of outcomes. We identified other potential 
design characteristics that might influence response rates but were unable to explore them in this 
analysis. These should be reported in future reports to allow for further investigation.  
Key words  
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What is new? 
 Multilevel linear regression was carried out to investigate what design characteristics 
were associated with response rates in studies that had included a Delphi study for COS 
development. Two characteristics were significantly associated with a lower response 
rate. COS studies with larger panel sizes had significantly lower response rates, and 
studies that included a higher number of items had significantly lower response rates. 
COS developers need to pay particular attention to these two features when designing 
a COS development study.  
 
 Other characteristics, all previously identified as potentially influencing response rates, 
including item order, length of time between rounds, length of time each round is open, 
format of feedback, and details of reminders, were not reported in the Delphi study 
reports. These details should be included in future reports to allow comparisons to be 
made. 
 
 The Delphi studies included in this study were predominantly e-Delphi studies. We were 
therefore unable to compare methods of delivery to investigate any impact this might 
have on response rate.  
 
 Studies within studies to answer research questions should be carried out, and will be 
an efficient and timely way to address the research uncertainties identified in this study. 
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1. Introduction 
Problems with outcomes measured in trials and wider health research are well documented. Problems 
include outcome reporting bias [1, 2], inconsistency in measuring and reporting of outcomes [3] and 
relevance to patients [4]. These problems can lead to the use of ineffective, or even harmful 
interventions, and to the waste of health care resources that are already limited [5]. These problems 
are being addressed by the development and application of core outcome sets (COS), the minimum 
agreed set of outcomes that should be measured and reported in all trials for a specific clinical area 
[6]. COS are also applicable in other settings such as for use in systematic reviews and routine care or 
audit. The focus of this paper is COS developed for research studies. When developing a COS, it is 
typical to first gain agreement about ‘what’ to measure, with decisions about ‘how and when’ to 
measure these outcomes later in the process [7]. This paper examines studies that have gained 
agreement about ‘what’ should be measured.  
Systematic reviews of COS demonstrate the growing number of COS developed for research [8-11], as 
well as an increase in the use of Delphi in their development [10]. This suggests that developers are 
increasingly adopting a more structured approach to COS development, which in turn has prompted 
the publication of the Core Outcome Measures in Effectiveness Trials (COMET) Handbook Version 1.0 
[7], to bring together accumulating methodological work in this area and offer recommendations for 
COS development.  
A systematic review of studies that used the Delphi technique to determine which outcomes to 
measure in clinical trials concluded that there was variability in both methodology and reporting [12]. 
This resulted in recommendations to improve the quality of studies that use the Delphi process for 
determining outcomes to use in clinical trials, including the recommendation that patients and 
clinicians be involved, researchers and facilitators avoid imposing their views on participants, and 
attrition of participants be minimised. Attrition of participants could mean that people with minority 
opinions drop out of the Delphi study, leading to an overestimation of consensus. The validity of the 
results will ultimately be affected by response rates [13].  It is therefore important to try to maximise 
response rates to a Delphi study, minimising attrition rates and therefore any potential attrition bias. 
Furthermore, qualitative interviews with COS developers highlighted response rates in Delphi studies 
for COS development as a priority area for further research and guidance [14].  
 
In the context of COS development, we are aware of only one empirical research study investigating 
the impact of design features on response rates. Brookes et al employed a parallel randomised 
controlled trial design nested within a Delphi survey for COS development, to explore the impact of 
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item order within a Delphi on the response rates [15]. The impact of item order within a Delphi survey 
showed that item order mattered, and health professionals appeared to have been less motivated to 
respond when clinical items appeared first. Response rates in Delphi studies for COS development 
have not previously been explored beyond this, and so the design characteristics that impact response 
rates in a Delphi study used for COS development are unknown.  
 
 
2. Aims 
The objective of this study was to explore the potential impact of different design characteristics on 
response rates in Delphi surveys within COS development projects. The following hypotheses were 
considered: 
1. The number of rounds will affect the response rate, with the expectation that response will 
decrease as the number of rounds in a Delphi increases.  
2. The number of items included in a round of voting will affect the response rate, with the 
expectation that Delphi response rates will be lower in studies that have included a higher 
number of items.  
3. The size of the panel will affect the response rate, with smaller panel sizes having a higher 
response rate. 
Other characteristics, including: single versus multi-disciplinary panels; international participation; 
format of feedback; length of time between rounds; length of time of each round; whether 
reminders were sent between rounds; mode of delivery, as well as acute vs chronic health 
conditions, were also considered.  
 
3. Methods 
 
3.1 Eligible studies  
3.1.1 Inclusion criteria  
A previous systematic review, with subsequent updates, of COS have identified 259 published studies 
up to and including December 2016 [8-11]. The methods of those reviews are reported in accordance 
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with PRISMA guidelines in the original publication [8]. Methodology reporting of older studies was 
poor; this study was therefore limited to more recently published studies in the hope that they would 
report relevant information and data. Studies from the three update reviews [9-11] that included 
Delphi in their methods to develop a COS were eligible for inclusion in this study.  
Ongoing studies that have used DelphiManager in the development of a COS, and that had completed 
the second round of voting in the study, were also eligible for inclusion in this study. These were 
identified via the DelphiManager software developer (RC). DelphiManager is a web based system 
designed to facilitate the building and management of e-Delphi surveys, and includes functionality 
allowing the researcher to email participants regarding missing responses, and view the accumulating 
response rates for rounds two and beyond. Permission was sought from each of the ongoing COS 
developers to include their data in this study.  
3.1.2 Exclusion criteria  
Delphi studies that did not report response data, or that did not report both a numerator and 
denominator for the response rate (for example, only reporting total percentage response rates), 
were excluded. Studies with only one round of voting were also excluded from this study. Studies that 
had not yet completed the second round of voting were excluded from this study.  
 
3.2 Data extraction  
First round response rates were described using varying denominators, including the number of 
participants invited and the number of participants who agreed to participate, making it difficult to 
combine, compare and contrast. We therefore analysed the response rates in the second rounds, 
where the denominator is the number of participants invited to the second round of voting. This was 
not necessarily the round named ‘round 2’ in the reports. Furthermore, some studies included an open 
first round for generating the list of outcomes therefore including a non-voting round. This was 
therefore not counted as a first round for the purposes of this study. Hereafter, when using the term 
‘response rate’ we are therefore referring to response rate in the second round. All ongoing study 
data included in the analysis and write-up of this study has been pseudo-anonymised, with the 
removal of identifiable features, such as place and person names. Details necessary for analysis (e.g. 
clinical area) were retained.  
The following information was extracted for each included Delphi study: 
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1. Study details including  
a. Surname of first author 
b. Year of publication 
c. Disease area/name  
 
2. Design 
a. Mode of delivery used  
b. Recruitment method  
c. Participant contact method  
d. Whether a reminder was sent between rounds (and method of reminder)  
e. Number of rounds  
f. Number of items included in each round  
g. Number of panels  
h. Format of feedback  
i. Length of time between each round 
 
3. Participants  
a. Stakeholder groups  
b. Countries  
 
4. Response rate  
a. Number of participants overall who completed each round  
b. Number of participants overall invited to complete each round  
c. Number of participants by panel who completed each round  
d. Number of participants by panel invited to complete each round  
 
Authors were contacted by email and asked to provide any missing data where possible. 
 
3.3 Analysis  
Multilevel linear regression was carried out to investigate whether Delphi design characteristics were 
associated with second round response rate. The models were fitted to reflect the panel structure 
within studies. The response variable in the model was the percentage response rate in the second 
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round for each panel. Independent variables included for each panel were; panel composition (mixed 
discipline/single discipline), size of panel invited to the second round, and whether the panel was 
international or based in a single country. Independent variables included for each study were; 
number of rounds in the study, number of items included in the second round. An initial model was 
fitted with random intercept. The effect of adding random slopes for each independent variable was 
explored by comparing the model fit using the AIC (Akaike Information Criterion). Models were fitted 
using PROC MIXED in SAS software version 9.4.  
Third and fourth round response rate data was not analysed due to the small sample size included in 
this study.  
 
4. Results  
Thirty studies from the systematic review updates [9-11] used Delphi methodology. Six studies did not 
report response rates, did not report response rate data that was useable, or only included one round 
of voting, and were consequently excluded from this study.   
Eight ongoing COS studies (as of February 2018) had completed the second round of voting using 
DelphiManager. Seven gave permission for their study data to be included and were therefore 
included in this study. The declined study author cited complex governance procedures, combined 
with personal circumstances, as the reason for not contributing to this study.  
These results therefore pertain to 31 studies; 24 published and seven ongoing studies that had used 
Delphi in the process of developing a COS.  
A descriptive summary of key characteristics is provided in Table 1. 
 
4.1 Overall response rates  
Overall sample sizes ranged from 9 to 678 (median 110). Response rates for the second round of voting 
ranged from 45% to 100%. These data, per study, are provided in Table 2. The overall response rate is 
typically 80% or higher, with only four studies where the overall response rate in the second round of 
voting is below this at 45%, 50%, 52%, and 64%. Email reminders were sent between first and second 
rounds of voting in nineteen studies to encourage participation and increase response rates.   
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4.1.1 Number of rounds  
Thirteen studies included two rounds, sixteen studies included three rounds, and two studies included 
four rounds (Table2). Studies that included two rounds had a range of response rates between 69% 
and 100%. Studies that included three rounds reported response rates of between 45% and 93%. The 
two studies with four rounds reported response rates of 80% and 86% respectively. Number of rounds 
was not significantly associated with response rate (p-value 0.634) (Table 3).  
 
4.1.2 Number of items  
Three studies did not report the number of items included per round, but this was provided for two 
studies when authors were contacted by email. This analysis therefore relates to 30 studies. The 
number of items included in the second round of voting ranged from 8 to 148, and the number of 
items per study is reported in Table 2.  
The multilevel linear regression analysis demonstrated a significant association between number of 
items and response rate in the second round (p-value 0.017) (Table 3), where studies with more items 
included in the second round had significantly lower response rates. The coefficient for number of 
items is -0.14, so for every 10 additional items included in the round, the estimated response rate 
drops by 1.4 percentage points. The association between number of items and response rate is 
displayed graphically in Figure 1.  
 
4.2 Response rates by panel  
The number of stakeholder panels per study ranged between one and eight. A summary is provided 
in Table 1, and by study in Table 2. In the study that had eight panels, one of the panels was not invited 
to participate beyond Round 1 (R1), and one was combined with another group after the first round 
of voting. These two panels are therefore excluded from further analysis, and this study is included as 
having 6 panels for the purpose of this study. Two panels were excluded from DelphiManager studies; 
one of the panels was not invited to participate beyond R1 and so is therefore excluded from further 
analysis, and another panel was excluded from the final analysis because it had a single member that 
did not respond to the second round, giving a 0% response rate. The analysis by panel therefore relates 
to 72 panels (summarised in Table 4, described in more detail in Appendix 1). 
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Studies that included only one panel had a response rate range of between 50% and 100%. Studies 
with two panels had panel response rates of between 75% and 94%. Studies with three panels had 
panel response rates of between 53% and 94%, and finally studies with four or more panels had panel 
response rates between 24% and 100%. 
In all but one of the published studies with multiple panels, feedback in the second round of voting 
was provided separately for each panel (i.e. the different stakeholder groups). In the one exception, 
feedback was provided at the start of the second round of voting as the mean scores and standard 
deviations for each outcome; they then provided scores by each stakeholder group at the start of the 
third round of voting. In all but one of the Delphi Manager studies, feedback in the second round of 
voting was provided separately for each panel. In the remaining study it was provided as combined 
percentage distribution across all panels.  
 
4.2.1 Panel size  
The only independent variable where allowing random slopes improved model fit was the size of the 
panel. Random slopes for this variable were added to the final model. The multilevel linear regression 
analysis demonstrated a significant association between the size of the panel and response rate (p-
value 0.035) (Table 3), where larger panels had significantly lower response rates. The coefficient for 
the panel size is -0.08; that is that the estimated response rate drops by 0.08 of a percentage point on 
average for every additional member. Therefore, as an example, for an additional 10 members 
estimated response rate dropped by approximately 0.8 of a percentage point, and for an additional 
50 members, it dropped by 4 percentage points. Figure 2 shows the association between size of panel 
and response rate.  
 
4.2.2 Panel composition  
The range of response rates in the second round for different stakeholder group panels was similar 
for each panel composition. If panels are considered as mixed (including those described here as 
multidisciplinary clinical experts and mixed) compared to those of a single discipline (including here 
the descriptors clinical experts’ single discipline, other and patient and public representatives) then 
the response rates are also similar. Panel composition (mixed vs single) was not significantly 
associated with response rate (p-value 0.598) (Table 3).  
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4.2.3 Participant countries  
25/72 panels (35%) only included participants from one country (national panels). National panels had 
response rates of 53% to 100%. The remaining 47 (65%) panels included participants from more than 
one country (international panels), between 3 and 25 countries in the 17 that reported this 
information (one from correspondence with author). International panels had response rates of 
between 24% and 100%. Participant countries (national vs international) was not significantly 
associated with response rate (p-value 0.882) (Table 3).  
 
4.3 Other characteristics  
Insufficient data was reported on the format of feedback provided, the length of time that each round 
was open and the length of time between rounds. We were therefore unable to consider these 
characteristics in the analysis. The Delphi studies included in this study were predominantly e-Delphi 
studies, that is delivered electronically, and therefore we were unable to compare against other 
modes of delivery such as postal. Finally, the COS in these Delphi studies were developed principally 
for chronic conditions, again making it impossible to make a comparison against COS for acute 
conditions.  
 
5. Discussion  
Multilevel linear regression was carried out to investigate whether design characteristics were 
associated with second round response rates in studies that had included a Delphi survey as part of 
COS development. Two characteristics were significantly associated with a lower response rate: larger 
size of panels, and studies with more items included in the second round.  
Studies that included a higher number of items had significantly lower response rates in the second 
round. It has previously been shown that odds of response increase for shorter surveys [16]. Use of a 
shorter list might minimise non-response, but this would need to be traded-off against the need for 
the list of outcomes to be comprehensive. Whilst it might be regarded as more comprehensive to 
retain outcomes through the rounds, retaining all outcomes through all rounds on a large list may be 
burdensome to participants and increase attrition between rounds [7]. If the decision is made to 
reduce the number of items between rounds to lessen the burden on participants, this should be 
clearly stated a-priori  and the criteria for doing so defined in advance to avoid bias [17].  
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COS studies with smaller panel sizes had significantly better response rates in the second round. The 
method of recruitment and participant contact at the start of the study might explain why smaller 
panels have higher response rates. Smaller panels were contacted directly by the study team (this 
information is only available for published studies, see Figure 3) compared to studies with larger 
panels that utilised an indirect approach of contact such as a website call through a charity or 
professional organisation or the method was unclear. Adopting a personalised approach has been 
suggested to increase odds of response for surveys more generally [16], and it would seem that this is 
also true for Delphi surveys in COS development.  
A Delphi study must consist of a minimum of two rounds (at least one round of feedback) to be 
considered a Delphi survey [7]. We hypothesised that the number of rounds would have an inverse 
association with response, as COS developers have previously expressed concern around retaining 
participants over the course of a study [14]. The number of rounds was not associated with second 
round response rates in this study. Furthermore, because the first round of voting was reported with 
varying denominators, we needed to analyse the second round of voting in this study. Participants in 
these studies were already committed to the study and so is likely to explain the high levels of 
response rates seen in the majority of COS Delphi studies included in this analysis.  
Panel composition was not associated with response rate when comparing panels of heterogeneous 
participants with panels of experts from one particular stakeholder group. We hypothesised that 
single discipline panels would have higher response rates because the outcomes rated by a 
homogenous group might be more or less relevant to that particular group, and so individual 
participants might identify more with the outcomes and therefore more likely to respond. However, 
with the exception of one study that had some differences in the outcomes being rated between 
panels, all panels within studies were presented with the same list of outcomes, which could explain 
why no difference was detected. Interviews are currently underway to explore participant 
perspectives on how relevant the list of outcomes was for them, and whether this affected their 
behaviour and decision on whether to complete the Delphi or not (personal communication).    
We hypothesised that response rates would decrease with international participation, but did not find 
an association between international panels and lower response rates. The number of countries 
included in the majority of international studies were not reported, so we were not able to explore 
this. Although this study did not find a significant association, the challenges of working internationally 
have been highlighted previously, including the resources required for international participation [7, 
14].  
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Sending a reminder in-between rounds has previously reported increasing odds of survey response by 
more than a quarter [16]. However, there are many underlying complexities in sending reminders, 
including whether it was an a priori or ad hoc decision, timing of reminder and length of time the 
round remains open following the reminder. COS study reports do not include such in-depth 
information about reminders, which meant we were unable to include this in the analysis in this study. 
Furthermore, the inclusion of whether a reminder was sent or not was not deemed reliable enough 
to include as a simple variable as reminder sent or not, as it was plausible that this might not have 
been reported for all studies where response rates were already regarded as high. A recent COS study 
asked participants about their experiences of participating in a COS Delphi, and it was concluded that 
participants did not find it bothersome to receive reminders to encourage timely voting [18]. 
Furthermore, another study has recently highlighted methods that worked well in relation to 
recruitment and retention, including the sending of reminders [19]. Reminders should continue to be 
sent in an attempt to maximise response.  
We identified other potential characteristics that might influence response rates, including the mode 
of delivery of the Delphi survey. Research has previously shown that internet based questionnaires 
are associated with lower response rates than postal [20]. Almost all of the studies included in this 
study were administered online, so we were unable to explore any potential differences between 
postal and e-Delphi surveys. Other factors, all previously identified as potentially influencing response 
rates [7, 15], including item order, length of time between rounds, length of time each round is open, 
format of feedback, as well as the aforementioned reminder complexities, were not reported in the 
Delphi study reports. These details should be included in future reports to allow comparisons to be 
made. Furthermore, studies within studies to answer research questions should be carried out and 
will be an efficient and timely way to address the research uncertainties identified in this study [21]. 
The final characteristic that we considered in relation to response rates in Delphi studies for COS 
development was whether the COS was developed for an acute or chronic disease population. 
Research in clinical trial recruitment has shown that in practice, recruitment and retention rates vary 
depending on this [22].  We were unable to analyse this for the Delphi COS studies included in this 
study because they were predominantly developed for chronic conditions.  
This is the first study to investigate the association of a range of characteristics to response rates in 
Delphi studies for COS development. By including ongoing COS as well as published, the conclusions 
drawn are current and likely to remain relevant to inform COS development for the foreseeable future. 
Ongoing studies were identified through the use of DelphiManager only, we therefore do not know 
the extent to which our findings might be relevant to ongoing COS Delphi studies using other software, 
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although it is not expected that these studies would have any differing characteristics.  The use of 
multilevel linear regression allows multiple panels within a single study to be included in the analysis, 
without the assumption that individual panels within a study are independent observations. It should 
be acknowledged that this was an exploratory analysis with a relatively small sample size, and that 
these results should be interpreted as indications of potential associations, and not definitive causal 
relationships. A larger study is needed to confirm these findings.  
In summary, this analysis showed that larger panels, and studies with more items included in the 
round, had significantly lower response rates. COS developers should pay particular attention to these 
characteristics when designing a COS development study. Suitable early planning is essential to 
optimise response rates in the Delphi process.  
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 Tables 
Table 1: A descriptive summary of key design characteristics    
Study characteristics (n=31) n (%) Panel characteristics (n=72) n (%) 
Number of rounds   Panel size   
2 13 (42) 1-50 44 (61) 
3 16 (52) 51-100 16 (22) 
4 2 (6) 101-150 4 (6) 
Method of Delivery   151-200 3 (4) 
e-delphi  25* (81) 201-250 2 (3) 
Post  3 (10) 251-300 2 (3) 
e-delphi (clinician) & post (patient) 2 (6) 301-350 0 (0) 
Not reported  1 (3) 351-400 1 (1) 
Number of panels   Panel composition  
1 14 (45) Clinical experts (multidisciplinary) 20 (28) 
2 8 (26) Clinical experts (single discipline) 19 (26) 
3 2 (6) Patient and public representatives 18 (25) 
4 1 (3) Mixed  8 (11) 
5 3 (10) Researchers 5 (7) 
6 1 (3) Funder 1 (1) 
7 1 (3) Commercial representative 1 (1) 
8 1 (3) Participant countries   
Number of items  National (one country only)  25 (35) 
1-50 17 (55) International (more than one country)  47 (65) 
51-100 10 (32) 
 
 
 
101-150 3 (10) 
Not reported  1 (3) 
Reminders sent between rounds  
Yes 19 (61) 
No/not known  12 (39) 
 
* Paper version available for patients on request in two studies 
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Table 2: Study details  
Study  Number 
of 
rounds  
Method 
of 
delivery  
Number of panels 
(panel composition) 
Number of 
items 
included in 
second 
round of 
voting 
Second round 
of voting total 
response 
 
N completed 
the round 
N invited to the 
round 
Second round of 
voting total 
response 
 
% 
Buch (2014) 2 e-delphi  1 (Mixed) 26 21/21 100 
Currie (2015) 2 e-delphi 1 (Clinical experts: 
multidisciplinary) 
32 33/33 100 
Major (2016)  3^ e-delphi 1 (Mixed)  87 10/10^ 100 
Ward (2014) 3^ e-delphi 1 (Experts in Yoga)  31 36/37^ 97 
Wylde (2014) 3 Clinician 
panel e-
delphi  
Patient 
panel 
paper by 
post  
2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
33 102/110 93 
Gerritsen 
(2016) 
2 e-delphi 
(but 
paper for 
patients 
available 
on 
request)  
2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
49 208/228 91 
Smelt (2014) 3 e-delphi 1 (Patient and public)  36 152/169 90 
Balakrishnan 
(2015) 
3 Not 
reported  
1 (Clinical experts: 
multidisciplinary) 
64 8/9 89 
van ʼt Hooft 
(2015) 
2 e-delphi 5 (Patient and public; 
Researchers; Clinical 
experts: single 
discipline x2; 
Researcher) 
31 174/195 89 
Helliwell 
(2016) 
3 e-delphi 
(but 
paper for 
patients 
available 
on 
request) 
~ 
2 (Patient and public; 
Clinical experts: 
multidisciplinary~) 
19 clinician 
panel/23 
patient 
panel~ 
 
101/115 88 
Milman 
(2017) 
3^ e-delphi 1 (Clinical experts: 
multidisciplinary) 
77~ 36/41^ 88 
Ismail (2016) 2 e-delphi 1 (Mixed) 51* 56/65 86 
Harman 
(2015) 
3 e-delphi 6 (Clinical experts: 
single discipline x6)+ 
47 85/99 86 
Haeusler 
(2015)  
4 e-delphi 1 (Mixed) 29** 37/43 86 
Potter (2015) 2 Post  2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
148 259/303 86 
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Eleftheriadou 
(2015)  
3 e-delphi 3 (Patient and public; 
Mixed; Clinical 
experts: single 
discipline) 
8 87/101 86 
McNair 
(2016) 
2 Post  2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
45 165/195 85 
Smith (2014) 2 e-delphi 1 (Clinical experts: 
single discipline) 
Not 
reported  
10/12 83 
Coulman 
(2016)  
3 Clinician 
panel 
paper by 
post OR 
e-delphi  
Patient 
panel 
paper by 
post 
2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
130 200/246 81 
Janssens 
(2014) 
4^ Post  1 (Clinical experts: 
multidisciplinary) 
22 227/285^ 80 
Fair (2016) 2 e-delphi 1 (Mixed)  13 93/117 80 
Al Wattar 
(2017) 
3 e-delphi 3 (Clinical experts: 
multidisciplinary  x2; 
Clinical experts: 
single discipline)  
48 48/75 64 
Audigé 
(2016) 
3 e-delphi 1 (Clinical experts: 
single discipline) 
9 69/132 52 
Chiarotto 
(2015) 
3 e-delphi 1 (Mixed)  51 130/261 50 
DM1 2 e-delphi 7 (Clinical experts: 
multidisciplinary  x2; 
Clinical experts: 
single discipline x3; 
Patient and public x 
1; Mixed x 1)  
100 141/205 69 
DM2 3 e-delphi 2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
57 86/93 92 
DM3 2 e-delphi 5 (Patient and public 
x 2; Clinical experts: 
multidisciplinary; 
experts: single 
discipline; 
Researcher) 
79 36/51 71 
DM4 3 e-delphi 6 (Patient and public 
x 2; Clinical experts: 
multidisciplinary; 
experts: single 
discipline x2; 
Researcher) 
114 187/416 45 
DM5 2 e-delphi 2 (Patient and public; 
Clinical experts: 
multidisciplinary) 
78 141/169 83 
DM6 3 e-delphi 5 (Patient and public; 
Clinical experts: 
multidisciplinary; 
68 581/678 86 
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Researcher; Funder; 
Commercial 
Representative)     
DM7 2 e-delphi 4 (Patient and public; 
Clinical experts: 
multidisciplinary; 
Researcher, Funder)     
36 74/76 97 
 
 
^ Round one was for generating the list of outcomes, so this is the response rate for round three (R3), 
as this is equivalent to the second round of voting in the other Delphi studies. 
*7 outcomes and 44 measures. 
**13 variables and 16 outcomes. 
+ The study had eight panels in R1: one was not invited to participate beyond R1, and one was 
combined with another group after the first round of voting. These two panels are therefore excluded 
here.  
~ Confirmed/provided through personal communication with the author. 
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Table 3: Results of the multilevel linear regression analysis 
 
 Coefficient 95% confidence interval p-value 
Panel level variables    
Panel composition (Mixed vs single) 1.44 (-4.15, 7.03) 0.598 
Size of panel -0.08 -(0.15, -0.01) 0.035 
International vs National 0.53 (-6.82, 7.89) 0.882 
Study level variables    
Number of rounds -1.57  (-8.31, 5.17) 0.634 
Number of items -0.14 (-0.25, -0.03) 0.017 
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Table 4: A summary of panels (see Appendix 1 for description)  
Stakeholder group Number of 
panels  
Range of 
response rates 
(%)  
Range of 
number of items  
Clinical experts 
(single discipline) 
19 52-100 8-114* 
Clinical experts 
(multidisciplinary)  
20 53-100 22-148 
Patient and public 
representatives  
18 24-94 8-148 
Mixed  8 50-100 8-100 
Other (single panels)^ 7 74-100 31-114 
Total 72   
 
*Not reported for one panel.  
^Includes 5 researcher panels, 1 funder panel and 1 commercial representative panel.  
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Figures  
 
 
Figure 1: Is there an association between the number of items included in the second round of 
voting and the response rate in the second round of voting?  
 
 
Figure 2: Is there an association between the size of the panel going into the second round of 
voting, the response rate in the second round of voting and the panel composition? 
 
Figure 3:  Panel size and method of contact   
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Appendix 1: A description by panel (n=72) of study recruitment methods and participant contact 
methods used in Delphi studies 
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Study Panel  Size of 
second 
round 
voting 
panel  
Second 
round of 
voting 
panel 
response 
% 
Study recruitment 
methods  
Participant 
contact method 
Number of 
countries 
(Counties)  
Harman (2015) Clinical experts 
(single discipline) 
9 100 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
Harman (2015) Clinical experts 
(single discipline) 
10 90 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
Harman (2015) Clinical experts 
(single discipline) 
13 92 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
Harman (2015) Clinical experts 
(single discipline) 
15 87 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
Harman (2015) Clinical experts 
(single discipline) 
17 82 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
Harman (2015) Clinical experts 
(single discipline) 
34 82 Clinical centres Individual 
participants 
emailed directly 
1 (UK) 
van ʼt Hooft 
(2015) 
Clinical experts 
(single discipline) 
62 89 Professional 
organisations  
A formal written 
invitation was e-
mailed to all 
members  
25 (not stated) 
van ʼt Hooft 
(2015) 
Clinical experts 
(single discipline) 
28 89 Clinical centres  
Professional 
organisations  
A formal written 
invitation was e-
mailed to all 
members of 
organisations 
25 (not stated) 
van ʼt Hooft 
(2015) 
Clinical experts 
(single discipline) 
34 100 Professional 
organisations  
A formal written 
invitation was e-
mailed to all 
members  
25 (not stated) 
Al Wattar (2017) Clinical experts 
(single discipline)   
14 93 Investigators’ email 
database 
Direct email  1 (UK) 
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Eleftheriadou 
(2015) 
Clinical experts 
(single discipline) 
51  
 
86 Professional 
organisations  
Email invite sent 24 overall – not 
broken down to 
panel (Algeria, 
Australia, 
Austria, Bahrain, 
Belgium, Brazil, 
Canada, 
Colombia, Egypt, 
France, 
Germany, 
Greece, India, 
Italy, Japan, 
Mexico, 
Morocco, the 
Netherlands, 
Saudi 
Arabia, Spain, 
Taiwan, Tunisia, 
United Arab 
Emirates, 
United Kingdom 
and United 
States of 
America.) 
Audigé (2016) Clinical experts 
(single discipline) 
132  52 Personal knowledge of 
experts  
Professional 
organisation/society  
Invited by email Numbers only 
reported for R3 
(international)  
Smith (2014) Clinical experts 
(single discipline) 
12 83 Publications  
Currently undertaking 
research 
Invited by email  10 (China, 
England, 
Australia, 
France, Italy, 
Spain, Canada, 
France, Holland, 
Japan) 
 
France included 
in the list twice  
Ward (2014) Clinical experts 
(single discipline) 
37 97 Publications 
Experts known to 
participants  
Personalised 
emails  
6 (US, Turkey, 
Brazil, UK, India, 
Sri Lanka)  
DM1 Clinical experts 
(single discipline) 
14 79 Not available   Not available   International~ 
DM1 Clinical experts 
(single discipline) 
92 60 Not available   Not available   International~ 
DM1 Clinical experts 
(single discipline) 
10 80 Not available   Not available   International~ 
DM4 Clinical experts 
(single discipline) 
83 75 Not available   Not available   International~ 
DM4 Clinical experts 
(single discipline) 
31 65 Not available   Not available   International~ 
Al Wattar (2017) Clinical experts 
(multidisciplinary) 
47  53 Investigators’ email 
database. 
Direct email  1 (UK) 
Al Wattar (2017) Clinical experts 
(multidisciplinary) 
14 71 Investigators’ email 
database. 
Direct email  1 (UK) 
Balakrishnan 
(2015) 
Clinical experts 
(multidisciplinary) 
9 89 Members of a 
taskforce/working group 
Not clear  Not reported  
28 
 
Wylde (2014) Clinical experts 
(multidisciplinary)  
39 90 Professional 
organisations  
Previous research 
participation 
Publications 
Experts known to 
participants  
Organizational 
gatekeepers were 
asked to 
disseminate 
study information 
via e-mail. 
3 (UK, Canada, 
Australia) 
Currie (2015) Clinical experts 
(multidisciplinary) 
33  100 Publications 
Known to experts  
Invited (assume 
by email as first 
round was sent by 
email)  
11 (not stated) 
Janssens (2014) Clinical experts 
(multidisciplinary) 
285 80 Professional societies  
Child Development 
Teams 
Professional 
societies 
forwarded 
invitations to 
their members 
 
Participants 
registered to take 
part 
using an online 
form 
1 (UK) 
Gerritsen (2016) Clinical experts 
(multidisciplinary) 
78 94 Professional 
organisations  
Electronic 
invitation 
1 (The 
Netherlands)  
Potter (2015) Clinical experts 
(multidisciplinary)   
88 78 Previous research 
participation 
Publications 
Invitation letter  
by post  
1 (UK)  
Coulman (2016) Clinical experts 
(multidisciplinary) 
157 76 Professional 
organisations  
Previous research 
participation 
Emailed/post by 
their society 
3 (UK, Republic 
of Ireland, 
Belgium) 
 
5 participants 
not specified 
McNair (2016) Clinical experts 
(multidisciplinary) 
98 80 Clinical centres Participants were 
approached by 
post 
1 (UK)  
Helliwell (2016) Clinical experts 
(multidisciplinary) 
60 92 Not clear  Not clear  Not reported 
(international) 
Milman (2017) Clinical experts 
(multidisciplinary) 
41 88 Professional 
organisations  
Email invite sent  18 (Canada, 
Mexico, US, 
Brazil, Chile, 
Peru, Denmark,  
Germany, 
Iceland, Italy, 
Netherlands, 
Spain, Sweden, 
UK, Japan, 
Turkey, 
Australia, New 
Zealand)  
DM1 Clinical experts 
(multidisciplinary) 
28 75 Not available  Not available International~  
DM1 Clinical experts 
(multidisciplinary) 
10 90 Not available  Not available International~ 
DM2 Clinical experts 
(multidisciplinary) 
52 92 Not available  Not available International~ 
DM3 Clinical experts 
(multidisciplinary) 
23 70 Not available  Not available 1 (UK) ~   
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DM4 Clinical experts 
(multidisciplinary) 
22 82 Not available  Not available International~ 
DM5 Clinical experts 
(multidisciplinary) 
102 89 Not available  Not available International~ 
DM6 Clinical experts 
(multidisciplinary) 
178 88 Not available  Not available International~ 
DM7 Clinical experts 
(multidisciplinary) 
19 100 Not available  Not available International~ 
Wylde (2014) Patient and public 
representatives  
71  
 
94 Previous research 
participation 
Sent a study pack 
(post) 
1 (UK)  
Coulman (2016) Patient and public 
representatives  
89 90 Clinical centres Invited to 
participate (I 
think post)  
1 (UK) 
McNair (2016) Patient and public 
representatives  
97 90 Clinical centres Participants were 
approached by 
post 
1 (UK) 
Gerritsen (2016) Patient and public 
representatives  
150  90 Clinical centres 
Patient organisations  
Clinical centre: all 
patients meeting 
the criteria were 
contacted by 
telephone and 
asked whether 
they would be 
willing to 
participate in the 
survey.  
 
Patient 
organisation: 
website call  
1 (The 
Netherlands) 
Smelt (2014) Patient and public 
representatives  
169 90 Patient database Invitation by 
email  
1 (The 
Netherlands) 
Potter (2015) Patient and public 
representatives  
215 88 Clinical centres Invitation letter  
by post  
1 (UK)  
van ʼt Hooft 
(2015) 
Patient and public 
representatives  
32 78 Patient organisations  Patient 
organisations 
approached 
members  
Not reported 
(international) 
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Eleftheriadou 
(2015) 
Patient and public 
representatives  
32 81 Patient organisations  Email invite sent 24 overall – not 
broken down to 
panel (Algeria, 
Australia, 
Austria, Bahrain, 
Belgium, Brazil, 
Canada, 
Colombia, Egypt, 
France, 
Germany, 
Greece, India, 
Italy, Japan, 
Mexico, 
Morocco, the 
Netherlands, 
Saudi 
Arabia, Spain, 
Taiwan, Tunisia, 
United Arab 
Emirates, 
United Kingdom 
and United 
States of 
America) 
Helliwell (2016) Patient and public 
representatives 
55 84 Not clear  Not clear  1 (UK) 
DM1 Patient and public 
representatives 
30 70 Not available  Not available  International~ 
DM2 Patient and public 
representatives 
41 93 Not available  Not available  International~ 
DM3 Patient and public 
representatives 
15 67 Not available  Not available  1 (UK) ~ 
DM3 Patient and public 
representatives 
4 75 Not available  Not available  1 (UK) ~ 
DM4 Patient and public 
representatives 
7 43 Not available  Not available  International~ 
DM4 Patient and public 
representatives 
238 24 Not available  Not available  International~ 
DM5 Patient and public 
representatives 
67 75 Not available  Not available  International~ 
DM6 Patient and public 
representatives 
359 84 Not available  Not available  International~ 
DM7 Patient and public 
representatives 
18 89 Not available  Not available  International~ 
Chiarotto (2015) Mixed  261  50 Publications 
Known to steering 
committee  
Invitations for 
participation were 
sent by email 
15 (US, The 
Netherlands, 
Australia, UK, 
Brazil, Italy, 
Norway, Canada, 
Spain, Belgium, 
Germany, 
Denmark, 
France, Finland, 
Switzerland) 
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Haeusler (2015) Mixed  43 86 Publications  
Clinical practice guideline 
panel  
E-mail invitations 
from the steering 
group 
19 (not stated) 
Eleftheriadou 
(2015) 
Mixed  18 94 Professional 
organisations  
Email invite sent 24 overall – not 
broken down to 
panel (Algeria, 
Australia, 
Austria, Bahrain, 
Belgium, Brazil, 
Canada, 
Colombia, Egypt, 
France, 
Germany, 
Greece, India, 
Italy, Japan, 
Mexico, 
Morocco, the 
Netherlands, 
Saudi 
Arabia, Spain, 
Taiwan, Tunisia, 
United Arab 
Emirates, 
United Kingdom 
and United 
States of 
America) 
Buch (2014) Mixed  21 100 Not clear Not clear 12 (not stated)  
 
10 European 
countries, the US 
and 
Canada 
Ismail (2016) Mixed  65 86 Professional organisation Potential 
participants were 
invited to take 
part by 
dissemination of 
an e-mail 
invitation and 
were asked to 
respond directly 
to the lead 
researcher  
Not reported 
(international) 
Fair (2016) Mixed  117 80 Research consortium 
Conference participants 
Survey distributed 
to the entire 
mailing list using a 
web-based 
platform  
Not reported 
(international) 
 
US and other  
Major (2016)  Mixed  10  100 Publications   Not clear  7 (Australia, 
Belgium, 
Canada, 
Netherlands, 
South Africa, UK, 
US) 
DM1 
 
Mixed 21 71 Not available  Not available  International~ 
van ʼt Hooft 
(2015) 
Researcher 39 90 Professional 
organisations  
A formal written 
invitation was e-
mailed to all 
members  
International~ 
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DM3 Researcher 8 88 Not available  Not available  1 (UK) ~ 
DM4 Researcher 35 74 Not available  Not available  International~ 
DM6 Researcher 92 93 Not available  Not available  International~ 
DM7 Researcher 35 100 Not available  Not available  International~ 
DM7 Funder  4 100 Not available  Not available  1 (US) ~ 
DM6 
 
Commercial 
Representative 
 
43 86 Not available  Not available  International~ 
 
~ Confirmed/provided through personal communication with the author. 
